CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

L. Carey, D. Berry, C. Cirrincione, et al.. (2016). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 362 times. https://doi.org/10.1200/JCO.2015.62.1268

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

A. Fernández-Martínez, I. Krop, D. Hillman, et al.. (2020). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Cited 89 times. https://doi.org/10.1200/JCO.20.01276

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

M. Golshan, C. Cirrincione, W. Sikov, et al.. (2016). Breast Cancer Research and Treatment. Cited 82 times. https://doi.org/10.1007/s10549-016-4006-6

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426)

Erica T. Warner, K. Ballman, C. Strand, et al.. (2016). Breast Cancer Research and Treatment. Cited 51 times. https://doi.org/10.1007/s10549-016-3918-5

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

D. Ollila, C. Cirrincione, D. Berry, et al.. (2017). Journal of the American College of Surgeons. Cited 9 times. https://doi.org/10.1016/j.jamcollsurg.2016.12.036